Amgen Inc. - Common Stock (AMGN)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 17, 2026Investment Snapshot
- Trading 366% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 75.7% with 23.6% net margin
- Revenue growing at 10% annually
Amgen Inc. - Common Stock (AMGN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $224.5 billion . Key value metrics: P/E ratio 25.4, P/B ratio 19.21, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Amgen Inc. - Common Stock — Fundamental Analysis Summary
Amgen Inc. - Common Stock (AMGN) is currently trading 366% above its Graham Number of $89.19, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 25.4x.
On financial health, AMGN shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 75.7% (sector average: -20.1%), and high leverage with a debt-to-equity ratio of 4.90.
StockPik's composite Value Score for AMGN is 67/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AMGN reports a high gross margin of 68.9% (sector average: 37.4%) and a strong operating margin of 30.4%.
AMGN shows revenue growing at 10% year-over-year, with earnings growing at 89%.
AMGN pays a modest dividend yield of 2.3%.